IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
IRONWOOD PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.56+0.06 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
33.3%−3.4 pts over 5 years
Net margin
8.1%−19.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -15.7% | -10.3% | -5.3% | +7.1% | |
| Operating income | +5.8% | -26.7% | -7.2% | – | |
| Net income | +2629.2% | -48.4% | -25.7% | – | |
| EPS, diluted | +1400.0% | -46.1% | -25.6% | – | |
| Free cash flow | +22.8% | -22.6% | -5.3% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -101.0% | -693.7% | -8.5% | |
| Return on assets | -12.3% | 22.1% | 6.4% | |
| Current ratio | 4.17 | 15.41 | 1.13 | |
| Debt to equity | 1.98 | – | – | |
| Net debt to EBITDA | -1.68× | – | – | |
| Interest coverage | -1.3× | 4.8× | 3.0× | |
| Capex to revenue | 1.5% | 0.5% | 0.0% | |
| Diluted shares | 145M | 161M | 163M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Ironwood Pharmaceuticals generated $949.68M from operations and spent $151.38M on capital expenditure, dividends and share buybacks. 1% of that went back into the business.
Generated
$949.68M
Used
$151.38M
Capital expenditure$850.00K1%Dividends$00%Share buybacks$150.53M99%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.1%
×Asset turnover0.79×
×Equity multiplier-1.33×
=Return on equity, FY2025-8.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.1% | 0.79× | -1.33× | -8.5% |
| FY2024 | 0.3% | 0.86× | -1.27× | -0.3% |
| FY2023 | -226.4% | 0.56× | 5.13× | -654.9% |
| FY2022 | 42.6% | 0.37× | 1.77× | 27.8% |
| FY2021 | 127.7% | 0.49× | 2.52× | 158.1% |
| FY2020 | 27.3% | 0.81× | -31.43× | -693.7% |
| FY2019 | 5.0% | 1.17× | -2.54× | -14.9% |
| FY2018 | -81.5% | 0.74× | -5.03× | 302.8% |
| FY2017 | -39.2% | 0.45× | 17.18× | -305.5% |
| FY2016 | -29.8% | 0.41× | 8.21× | -101.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$24.02M
- Cash generatingOperating cash flow above zero$127.04M
- Return on assets improvedROA up on the prior year0.2% → 6.8%
- Earnings backed by cashOperating cash flow above net income$127.04M vs $24.02M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.69 → 1.13
- No dilutionShare count did not rise160M → 163M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.75 → 0.84